Shanghai Xingling Science & Technology Pharmaceutical Co. and U.S. CRO Quintiles Transnational Corp. have agreed to apply jointly for market entry approval for Xingling's ginkgo extracts from the U.S. Food and Drug Administration, according to the May 22 Chinese Medical News.

Shanghai Xingling's ginkgo flavonoids and terpene lactones and Xingling granules are Class II new drugs protected for eight years in China.

Recommended by the Ministry of Science & Technology and the Shanghai Scientific Committee, they have passed preliminary evaluations for new drug applications by the U.S. FDA. Their production technology and clinical application have been granted patents in China and the United States.

From Sohu.com